ArticleJournal of intensive care2026
Subphenotype-specific serum proteomic signatures in patients with ARDS.
Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute respiratory distress syndrome (ARDS) is associated with a substantial burden of morbidity and mortality. Previous studies have identified reproducible hyperinflammatory and hypoinflammatory ARDS subphenotypes with distinct clinical outcomes and treatment responses. Although recent transcriptomic studies have provided insights into biological differences between these subphenotypes, the role of the circulating proteome remains incompletely understood.
methodsIn this prospective study, patients with ARDS were classified into hyperinflammatory or hypoinflammatory subphenotypes using a previously validated 3-variable classifier based on bicarbonate, interleukin-6, and soluble tumor necrosis factor receptor 1. Serum proteomic profiling was performed to identify differentially abundant proteins between subphenotypes. Biological pathways were examined using gene set enrichment analysis. To provide cellular expression context for the subphenotype-associated serum proteins, serum proteomic data were mapped onto publicly available single-cell RNA-seq datasets from peripheral blood mononuclear cells, neutrophils, and tracheal aspirates.
resultsAmong 31 patients with ARDS, 13 (42%) were classified as having the hyperinflammatory subphenotype and 18 (58%) as having the hypoinflammatory subphenotype. Both 28-day and in-hospital mortality were higher in the hyperinflammatory subphenotype than in the hypoinflammatory subphenotype (46% vs. 11%, P=0.04; 62% vs. 11%, P=0.01, respectively). In total, 54 serum proteins were differentially abundant between subphenotypes. These proteins represented biologically relevant categories, including endothelial injury, immunoregulation, coagulation/fibrinolysis, complement regulation, tissue remodeling, and metabolism-related proteins. Gene set enrichment analysis identified pathways differentially enriched between subphenotypes, including cell adhesion, cell-cell signaling, and cytokine responses (all FDR < 0.10). In external single-cell RNA-seq reference datasets, genes encoding the subphenotype-associated proteins were expressed predominantly in CD14 and CD16 monocytes in PBMCs, showed distinct expression patterns across immature and CD163+IL1R2^hi^ circulating neutrophil states, and were expressed mainly in macrophage and monocyte populations, with additional epithelial expression, in tracheal aspirates.
conclusionsSerum proteomic profiling identified distinct protein patterns associated with established ARDS inflammatory subphenotypes, providing insights into the biological heterogeneity of ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.